Anti-Α-Galactosidase: Anti-Body Riposte to Agalsidase Beta Growth in Fabry Disease Patients by Ahmad, Muhammad Naveed et al.
ISSN: 2321-8819 (Online) 2348-7186 (Print) Impact Factor: 1.498 Vol. 6, Issue 3, March, 2018  
246 
Asian Journal of Multidisciplinary Studies, 6(3) March, 2018 
 
  
  
 
 
 
Anti-Α-Galactosidase:  
Anti-Body Riposte to Agalsidase Beta Growth in Fabry Disease Patients 
 
Muhammad Naveed Ahmad1, Zeeshan Nasir2 and Daniyal Qayyum3 
1Shalamar Medical & Dental College, Lahore, Pakistan 
Email: naveed2686@gmail.com 
2Medical Officer at DHQ Hospital Sheikhupura, Pakistan 
Email: thegreatzeeshan@yahoo.com 
3Shalamar Medical & Dental College, Lahore, Pakistan 
Email: daniyal.qayyum@gmail.com 
 
ABSTRACT 
Fabry disease is a X-connected lysosomal stockpiling 
issue caused by an inadequacy in α-galactosidase A (α-
lady A). Catalyst substitution treatment (ERT) comprises 
of general mixtures of recombinant α-lady A. Fabry 
sickness patients usually create IgG antibodies against 
this catalyst and there is a worry that they may decrease 
the viability and security of ERT. We built up an ELISA 
to quantify hostile to α-lady An IgG antibodies and found 
that 61% of patients on ERT were seropositive. We 
likewise composed a quick, single-chromatography 
cleaning convention for α-lady A from the supernatant of 
a human embryonic kidney 293T cell line built to 
steadily overexpress a 6xhis-labeled human α-lady A. 
We got 0.342 mg/L with the normal sub-atomic weight 
yet bring down enzymatic action than anticipated. This 
α-lady An is bound by antibodies from seropositive 
patients and not by those from solid people, which 
recommends that it might fill in as antigen in our ELISA 
to quantify against α-lady An antibodies. 
 
Keywords: anti-α-galactosidase, antibody, 
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INTRODUCTION  
Fabry disease (also known as Anderson-Fabry 
Disease, angiokeratoma corporis diffusum and α- 
galactosidase A (α-gal A) deficiency; OMIM 
#301500) results from mutations in the GLA gene 
which cause deficiencies in the enzyme it encodes, 
α-gal A (EC 3.2.1.22), and the accumulation of 
glycosphingolipids, particularly Gb3 (Brady et al. 
1967). Fabry disease has an X-linked inheritance 
and an estimated incidence of 1:40,000 in males 
(Meikle et al. 1999; Robert J. Desnick, Ioannou, and 
Eng 2001) but neonatal screenings have shown 
much higher incidences of 1:1,250 males in Taiwan 
(Hwu et al. 2009), 1:2,913 individuals in Missouri 
(Hopkins et al. 2015), 1:3,024 in Japan (Inoue et al. 
2013), 1:3,100 in Italy (Spada et al. 2006) and 
1:3,859 in Austria (Mechtler et al. 2012). Quality 
of life of Fabry disease patients is negatively 
impacted (Arends, Hollak, and Biegstraaten 2015) 
and life expectancy is reduced by approximately 20 
years in males (K. D. MacDermot, Holmes, and 
Miners 2001b) and 15 years in females (K. D. 
MacDermot, Holmes, and Miners 2001a). 
Table 1. Sphingolipid-accumulating LSDs. Some 
of the LSDs characterized by sphingolipid 
accumulation and the proteins that are defective in 
each. All are lysosomal hydrolyses with the 
exception of NPC1 and NPC2, which are 
lysosomal membrane proteins involved in 
intracellular lipid transport (Ioannou 2000). 
 
Disease 
 
Sphingolipid 
accumulated 
 
Defective protein 
 
Farber 
 
Ceramide 
 
Acid ceramidase 
 
Krabbe 
 
GalCer 
β-
galactosylceramidase 
 
Gaucher 
 
GlcCer 
 
Glucocerebrosidase 
 
Metachromatic 
leukodystrophy 
 
Sulfatide 
 
Arylsulfatase 
 
Fabry 
Gb3, 
galabiosylceramide 
 
α-galactosidase A 
 
Sandhoff 
Gb4  
β-Hexosaminidase 
 
Niemann-Pick 
type C 
All GSLs, 
cholesterol, 
sphingomyelin and 
sphingosine 
NPC1, NPC2 
To date, the preferred treatment for Fabry disease 
consists of the intravenous infusion of recombinant 
human α-gal A to supplement the deficiency of this 
enzyme. Development of circulating IgG 
antibodies against this recombinant α-gal A is 
common among Fabry disease patients receiving 
ERT, occurring in 11 to 91% of male patients, an 
incidence that appears to depend greatly on the 
enzyme preparation (agalsidase alfa or beta) that 
the patient is treated with (J. T. R. Clarke et al. 
2007; Germain et al. 2007). 
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Thus far, there is conflicting evidence regarding the 
possible effect these antibodies may have on 
important biomarkers of Fabry disease such as 
plasma Gb3 or lyso-Gb3 (Eng, Banikazemi, et al. 
2001; Wilcox et al. 2004; Hughes et al. 2008; 
Anouk C. Vedder et al. 2008; Wraith et al. 2008; 
Anouk C. Vedder et al. 2007; van Breemen et al. 
2011; Rombach et al. 2012; Wilcox et al. 2012) and 
urinary Gb3 (Raphael Schiffmann, Ries, et al. 2006; 
Ohashi et al. 2007; Anouk C. Vedder et al. 2007; 
Hughes et al. 2008; Anouk C. Vedder et al. 2008; 
Lubanda et al. 2009; Rombach et al. 2012). 
Nevertheless, there is a concern that these 
antibodies may have the potential to reduce the 
efficacy of ERT as they have been shown to bind to 
α-gal A in the circulation (Linthorst et al. 2004), to 
inhibit uptake of α-gal into cells in vitro and in an 
animal model (Ohashi et al. 2008), and to inhibit 
enzyme activity in vitro (Linthorst et al. 2004; Ries 
et al. 2006; Ries et al. 2007; Ohashi et al. 2008). In 
addition, it is possible that anti-α-gal A antibodies 
generated against agalsidase alfa or beta affect 
future second generation α-gal A preparations, 
chaperone treatment that promotes the stability of 
the patient’s endogenous mutated α-gal A or gene 
therapy for Fabry disease. For these reasons, anti-
α-gal A IgG antibodies are routinely monitored in 
many on-going ERT clinical trials such as the 
Canadian Fabry Disease Initiative 
(ClinicalTrials.gov identifier: NCT00455104). 
With this in mind, the aims of this study were: (1) 
to develop an ELISA protocol to measure the levels 
of anti-α-gal A IgG antibodies in the serum of 
Fabry disease patients and (2) to purify a human α-
gal A that can be used in the future to titer anti-α-
gal A IgG antibodies. Because the α- gal A used as 
antigen in our ELISA was a gift from Dr. Roscoe 
Brady, we sought to purify our own human α-gal A 
for future antibody titering. Agalsidase alfa and 
beta are expressed and purified from the culture 
medium of CHO cells and human fibroblasts, 
respectively (Lee et al. 2003). Because 
glycosylation patterns affect the antigenicity of 
recombinant proteins (Brooks 2004), we sought to 
purify a human α-gal A with human post-
translational modifications. Therefore, we chose to 
express our enzyme in human embryonic kidney 
(HEK) 293T cells. We utilized the PiggyBac™ 
transposon system to generate a stable cell line that 
overexpresses a his- tagged human α-gal A. We 
then optimized an affinity chromatography protocol 
and characterized the product obtained. Finally, we 
showed that our purified α-gal A is bound by 
antibodies present in seropositive patients and not 
by those present in healthy individuals, which 
suggests that it may be suitable to use as antigen in 
our ELISA to measure anti-α-gal A antibody levels. 
The mature α-gal A is a soluble homodimeric 
glycoprotein of a native molecular mass of 101 kDa 
(Bishop and Sweeley 1978; Kusiak, Quirk, and 
Brady 1978; Dean and Sweeley 1979; Bishop and 
Desnick 1981). Each monomer is composed of two 
domains (Fig. 1.6.a) (S. C. Garman and Garboczi 
2004). Domain 1 includes residues 32 to 330 while 
domain 2 is comprised of residues 331 to 429 (S. 
C. Garman and Garboczi 2004). The homodimer 
has protein dimensions of approximately 75 Å x 75 
Å x 50 Å (Fig. 1.6.b-c) and 30 residues from each 
monomer contribute to the dimer interface (S. C. 
Garman and Garboczi 2004). Each monomer 
contains five disulfide bonds (C52–C94, C56–
C63, C142–C172, C202–C223, and C378–C382) 
(S. C. Garman and Garboczi 2004). 
 
Figure 1. 3D structure of α-gal A. (a) The α-gal A 
monomer. (b) and (c) Two views of the α-gal A 
homodimer. The monomer is colored from N (blue) 
to C (red) terminus. The galactose ligand in the 
active site is shown in yellow and red CPK atoms. 
Image taken from Garman and Garboczi (2004). 
The active site cleft is found in a broad opening on 
the concave surface of the enzyme (Fig. 1.6.c) (S. 
C. Garman and Garboczi 2004). Residues from 
seven loops in domain 1 form the active site: W47, 
D92, D93, Y134, C142, K168, D170, E203, L206, 
Y207, R227, D231, D266, and M267, with C172 
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making a disulfide bond to C142 (S. C. Garman 
and Garboczi 2004). The side chains of these 
residues make specific contacts to each functional 
group on α-galactose (Fig. 1.7). α-gal A shows 
little specificity for the distal portion of the 
substrate beyond the glycosidic linkage (S. C. 
Garman and Garboczi 2004). 
 
Figure 2. α-gal A active site interactions with α-
galactose. α-galactose is in bold and the side chains 
of the residues of α-gal A that comprise the active 
site are labeled. Hydrogen bonds and polar 
interactions are in red and van der Waals 
interactions are in blue. Image taken from Garman 
and Garboczi (2004). 
 
The α-gal A homodimer is negatively charged at 
neutral pH as each monomer has 47 carboxylate 
groups and 36 basic residues (S. C. Garman and 
Garboczi 2004). The isoelectric point of the plasma 
α-gal A is 4.2 (Bishop and Sweeley 1978; Bishop 
and Desnick 1981) while the tissue forms range in 
pI from 4.3 to 5.1 (Beutler and Kuhl 1972; Dean 
and Sweeley 1979; Bishop and Desnick 1981; 
Kusiak, Quirk, and Brady 1978). These variations 
result from differing amounts of sialic acid on the 
carbohydrate chains (Bishop and Desnick 1981). 
Materials and methods 
Ten mL of blood were drawn from five healthy 
controls and 49 male Fabry disease patients. Blood 
was collected in EDTA-coated tubes, plasma was 
separated from cells by centrifugation at 1377 x g 
for 5 minutes at room temperature and 
subsequently aliquoted. Aliquots to be used in the 
immediate future were stored at 4 °C and the rest 
were stored at -80 °C. LVH was determined by 
MRI. The data were kept anonymous. 
RESULTS 
Anti-α-gal A IgG antibody levels 
We used the α-gal A gifted to our lab by Dr. Brady 
as antigen to measure the levels of anti-human α-
gal A IgG antibodies in the serum of Fabry disease 
patients by ELISA. As part of the validation of this 
protocol, the ERT status of these patients was only 
disclosed after analysis.  
Overall, 61% of patients on ERT were seropositive 
in this study. Age was not significantly different 
between seropositive and seronegative patients that 
received ERT (mean of 46 and 47 years, 
respectively). 58% of patients on agalsidase alfa 
were seropositive while 80% of patients on 
agalsidase beta were seropositive (Fig. 3.1.a). Age 
was not significantly different between the two 
groups (mean of 46 and 49 years, respectively). 
There was no correlation between agalsidase 
preparation and development of anti-α-gal A 
antibodies. However, it must be noted that the 
sample size of patients on agalsidase beta was 
small (n = 5). Similarly, there was no correlation 
between mutation type and development of 
antibodies (Fig. 3.1.b) or antibody levels (Fig. 
3.1.c). 
GFP expression in HEK293T cells transfected with 
PB513B-1.α2 and PB513B-1.f1 compared to non- 
transfected cells 23 days post-transfection assessed 
by flow cytometry. (b) α-gal A activity was 
analyzed intracellularly and in the culture 
supernatant of α2 cells, f1 cells and NT cells. In 
each experiment, the same number of cells were 
plated for each cell line, cells were cultured for the 
same length of time, samples were collected 
simultaneously and α-gal A activity was 
determined in the same assay. Data represent mean 
± SEM (n = 2-3). *P < 0.05, **P < 0.01, ***P < 
0.001. (c) Samples were obtained lysing the same 
number of cells in the same volume of lysis buffer 
and the same volume of each was run in a 12% gel. 
The membrane was stained with an anti-human α-
gal A antibody. α2: HEK 293T cells transfected with 
a plasmid containing the full cDNA sequence of α-
gal A; f1: HEK 293T cells transfected with a 
plasmid containing a truncated cDNA sequence of 
α-gal A; GFP: green fluorescent protein; NT: HEK 
293T cells not transfected. 
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Figure 3. Purity of his-tagged α-gal A purified 
from cell lysate or culture supernatant. Samples 
were taken from the pooled elution fractions of 
chromatography performed on each source of 
protein. SDS- PAGE (12%) was performed and the 
gel was visualized by silver stain. CL: cell lysate; 
sup: culture supernatant. 
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Figure 4. Adaptation to grow with less FBS did 
not reduce production of α-gal A by α2 cells 
while decreasing protein contaminants. (a) The 
same volume of culture supernatant obtained from 
growing the identical number of α2 cells for the 
same length of time was run in a 12% gel and 
protein was visualized by silver stain. (b) α-gal A 
activity was analyzed intracellularly and in the 
culture supernatant of α2 cells adapted to grow 
with 7.5%, 5% and 4% FBS in the culture medium, 
and compared to α2 cells that grow with 10% FBS. 
In each experiment, the same number of cells were 
plated for each cell line, cells were cultured for the 
same length of time, samples were collected 
simultaneously and α-gal A activity was 
determined in the same assay. Data represent mean 
± SEM (n = 2-4). NS: not significant; ***P < 
0.001. 
 
Figure 5. His-tagged α-gal A present in 
chromatography fractions. Western blot of 
fractions of an affinity chromatography performed 
on 500 mL of culture supernatant from α2 cells 
adapted to grow with 4% FBS. The same volume of 
all fractions was run in 12% gels and each 
membrane was stained with either an anti-human α-
gal A (top) or an anti-6xHis (bottom) antibody. 
Lane 1: culture supernatant used as source for 
chromatography; lane 2: chromatography flow-
through; lanes 3-5: consecutive washes done with 
washing buffer (50 mM imidazole); lanes 6-8: 
consecutive elutions done with elution buffer (250 
mM imidazole); lane 9: molecular weight marker; 
lane 10: a mixture of a purified α-gal A (gifted by 
Dr. Roscoe Brady) and a purified his-tagged 
protein of ~27 kDa (gifted by Zhenhao Fang from 
the Ikura Lab). 
Characterization of the purified α-gal A 
In order to obtain a greater yield, the elution 
fractions obtained from 8 purifications performed 
as described were combined into approximately 
100 mL. Because a high concentration of imidazole 
such as the one present in the elution buffer can 
interfere with the ultrafiltration filter device used to 
concentrate the sample, we first desalted it using a 
size-exclusion chromatographic resin to separate 
proteins from small molecules (smaller than 2 
kDa). Immediately after desalting, the enzyme was 
concentrated using a filter with a molecular weight 
cut-off of 30 kDa. Desalting and concentrating 
reduced the sample volume from 100 mL to 4 mL. 
Protein concentration in this final sample was 0.342 
mg/mL as determined by BCA assay, for a yield of 
1.368 mg of protein. α-gal A activity in this sample 
was determined to be 969.78 nmol/h/mg. 
This sample was visualized on an SDS-PAGE as a 
thicker band of approximately 55 kDa, a size that 
corresponds with the denatured α-gal A (Fig. 3.7, 
lane 1). This band is also present in the α- gal A 
preparation used in our ELISA (Fig. 3.7, lane 3). 
Our preparation had a few, fainter other bands, 
mostly of greater molecular weight. We also 
confirmed that our purified α-gal A was N- 
glycosylated because treatment with PNGase F, 
which cleaves the innermost GlcNAc of high 
mannose, hybrid and complex oligosaccharides 
from asparagine residues, resulted in a decrease in 
molecular weight of α-gal A similar to that of the α-
gal A gifted to us by Dr. Brady (Fig. 3.7, lanes 2 and 
4, respectively). 
Discussion 
Our analysis suggests that our his-tagged α-gal A is 
adequately processed by the cell machinery, 
although the smaller band detected by the anti-α-
gal A and the anti-his antibodies suggests that some 
of our enzyme is partially degraded either before or 
after reaching the extracellular medium. Cleavage 
of the signal peptide could be confirmed in the 
future by N-terminal sequencing. De- glycosylation 
and SDS-PAGE analysis indicates that our 
recombinant α-gal A seems to be glycosylated 
similarly to the α-gal A used in our ELISA protocol 
that was donated by Dr. Brady. The glycosylation 
pattern of an α-gal A expressed in HEK 293T cells 
should not differ significantly from that occurring in 
other human cells. However, the exact nature and 
proportions of the glycosylations of our enzyme 
should be studied in the future because of their 
effect on the antigenicity of recombinant proteins 
(S. A. Brooks 2004), an aspect that is highly 
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relevant to the intended use of this purification 
product. 
The specific enzymatic activity of our α-gal A was 
much lower than that of commercial α-gal A 
(969.78 and 3,870,000 nmol/h/mg, respectively. 
The latter was determined by Lee et al., 2003). This 
may be caused by the his tag added to the C-
terminus of our recombinant protein. Miyamura et 
al. (1996) determined that α-gal A activity 
increased when 2-10 residues of the C-terminus of 
the human protein were deleted, whereas deletions 
of 12 or more residues resulted in inactive 
enzymes. In the agalsidase alfa and beta 
preparations, a significant percentage of the α-gal 
A molecules lack one or two residues of the C-
terminus, which may confer a higher enzymatic 
activity to these drugs (Lee et al. 2003). In the 
coffee bean α-gal A, deletion of more than four 
residues rendered an inactive enzyme (Maranville 
and Zhu 2000). More importantly, the same 
occurred when this α-gal A was fused at the C-
terminus to GFP or to other glycosidases 
(Maranville and Zhu 2000). Alteration of the C-
terminus in our his-tagged α-gal A could be the 
cause of its low activity compared to the 
commercial non-tagged preparations. If this were 
the case, designing an α-gal A without a few of the 
C-terminus residues and/or removal of the his tag 
are potential strategies to increase the specific 
activity of the enzyme. 
In our case, however, it is possible that the his tag 
only partially explains the reduced enzyme activity. 
Corchero et al. (2011) also utilized a 6xhis tag on 
the C-terminus to purify human α-gal A from HEK 
293 cells but the specific activity of their purified 
enzyme was only 2-fold lower than that of 
commercial α-gal A. Given that their purification 
process was very similar to ours (6xhis tag on the 
C-terminus, purification from supernatant, filtration 
of supernatant prior to IMAC, elution with 
imidazole and buffer exchange), it would appear 
that a factor other than the his-tag on the C-
terminus and our purification strategy causes such a 
reduction in enzymatic activity. In the study by 
Corchero et al. (2011), both Western blot and SDS-
PAGE show a single band corresponding to α-gal 
A. This indicates that there is no degraded enzyme 
and no protein contaminants present in their 
purified product (although they used Coomassie 
staining, which is less sensitive than silver 
staining), as opposed to ours. Since α-gal A specific 
enzymatic activity is calculated based on total 
protein present in the sample, it is possible that 
the lower activity measured in our product is in 
part due to an overestimation of the amount of 
intact α-gal A in the sample, i.e., that there are 
protein contaminants and partially degraded α-gal 
A molecules that do not contribute to the 
degradation of the substrate in the activity assay but 
are nevertheless included in the specific activity 
calculations. In addition to this, the oligomeric 
status of the native purified α-gal A should be 
assessed in the future by size-exclusion 
chromatography (SEC) because a large percentage 
of the molecules remaining as monomers would 
also explain the lower enzymatic activity observed. 
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